B.K.S. Sastry

Bringing Imaging to the Bedside: The Growing Impact of Point-of-Care Ultrasound in Pediatric and Neonatal Intensive Care

Swetha Manoj, Akshitha Talasila, Pallak Khattar, B.K.S. Sastry et autres

Point-of-care ultrasound (POCUS) is becoming increasingly integral to pediatric and neonatal intensive care, offering real-time, radiation-free imaging that enhances diagnostic precision and procedural safety. This narrative review synthesizes current evidence on its clinical applications, benefits, training models, and future directions in pediatric …

in, np, jo (code pays fourni par la source)

Current status and barriers in pulmonary hypertension care delivery in India: A qualitative analysis

Anand Reddy Maligireddy, Supriya Shore, Aman Kumar, S Harikrishnan et autres

Although pulmonary hypertension (PH) is widely prevalent in India, care delivery for this condition has unique challenges in a lower middle-income country (LMIC). To describe care delivery for patients with PH and associated barriers in India. We interviewed physicians across eight healthcare …

us, in (code pays fourni par la source)

SAFETY AND EFFICACY OF MACITENTAN IN ELDERLY PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM SERAPHIN

David Langleben, Richard N. Channick, Marion Delcroix, Nazzareno Galiè et autres

fr, ch (code pays fourni par la source)

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases

Adam Torbicki, Marisa Bacchi, Marion Delcroix, Harrison W. Farber et autres

Background Conducting randomized controlled trials to investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical and logistical constraints. In many studies, such as the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome …

it, ch, be, us, de, cz, ca, mx, in, fr, br (code pays fourni par la source)

One-year clinical outcomes of different coronary drug eluting stents—Data from a prospective registry

B.K.S. Sastry, Krishna Reddy Nallamalla, Nirmal Kumar, Kodati Deepti et autres

We compared one-year clinical outcomes of different drug eluting stents (DES) used in a prospective observation registry maintained in two hospitals over three years. The primary endpoint was combination of all-cause mortality, stent thrombosis and revascularization. There was no significant difference among …

in (code pays fourni par la source)

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial

Rogério Souza, Richard N. Channick, Marion Delcroix, Nazzareno Galiè et autres

BACKGROUND: Patients with pulmonary arterial hypertension who achieve a six-minute walk distance of 380-440 m may have improved prognosis. Using the randomized controlled trial of macitentan in pulmonary arterial hypertension (SERAPHIN), the association between six-minute walk distance and long-term outcomes was explored. …

br, us, be, it, de, gb, cz, ch, ca, mx, in, fr (code pays fourni par la source)

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

Vallerie V. McLaughlin, Marius M. Hoeper, Richard N. Channick, Kelly Chin et autres

BACKGROUND: Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) is indicative of poor prognosis. However, the prognostic relevance of PAH-related morbidity has not been formally evaluated in randomized controlled trials. OBJECTIVES: The purpose of these analyses was to assess …

us, de, ie, gb, cz, at, ca, mx, in, fr, br, ch, it (code pays fourni par la source)

Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension

Carmine Dario Vizza, B.K.S. Sastry, Zeenat Safdar, Lutz O. Harnisch et autres

BACKGROUND: In a previous study, 6-minute walk distance (6MWD) improvement with sildenafil was not dose dependent at the 3 doses tested (20, 40, and 80 mg 3 times daily [TID]). This study assessed whether lower doses were less effective than the approved …

it, in, us, gb, cn (code pays fourni par la source)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension

Nazzareno Galiè, Pavel Jansa, Tomás Pulido, Richard N. Channick et autres

Aims: The effect of macitentan on haemodynamic parameters and NT-proBNP levels was evaluated in pulmonary arterial hypertension (PAH) patients in the SERAPHIN study. Association between these parameters and disease progression, assessed by the primary endpoint (time to first morbidity/mortality event), was explored. …

cz, mx, us, be, de, gb, ch, ca, in, fr, br (code pays fourni par la source)

Severe PAH with Renal Failure

B.K.S. Sastry

A 32 Year Male patient by name K.KONDAIAH R/O Nalgonda was admitted on 18-07-2016 with complaints of Shortness of breath for one month, pedal edema for 2 days, decreased urine output for one day.He was apparently asymptomaic 1 month back and the …

in (code pays fourni par la source)

Titre indisponible

B.K.S. Sastry

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN

Gérald Simonneau, Richard N. Channick, Marion Delcroix, Nazzareno Galiè et autres

In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve incident and prevalent cohorts.Patients allocated to placebo, or …

fr, us, be, it, de, gb, cz, ch, ca, mx, in, br (code pays fourni par la source)